Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

Autor: Silvio Danese, V. Yajnik, P. Gionchetti, Brian G. Feagan, Richard N. Fedorak, O. Dewit, D. Sorrentino, V. F. Annese, W J Sandborn, Michael Chiorean, G. Radford-Smith, S Plevy, I. Lawrance, Jane E. Onken, Simon Campbell, Jewel Johanns, Peter L. Lakatos, G R D’Haens, Denis Franchimont, J. C. Preiss, Giovanni Terrosu, Áron Vincze, Torsten Kucharzik, Charles Randall, I. Stein, Edward V. Loftus, L. Sauberman, X. Li, I. Oikonomou, Frank Zerbib, H. G. Lamprecht, R. Kottoor, J. Vecchio, Severine Vermeire, Daniel Rachmilewitz, J. R. Lachance, J.L. Dupas, W. H. Holderman, Michael Safdi, T. Haas, J.-F. Colombel, Richard B. Gearry, Russell S. Walmsley, R. P. Phillips, Miguel Regueiro, A. B. Hawthorne, David T. Rubin, J. W. Hamilton, G. D'Haens, M Parkes, Jean-Marie Reimund, Fabrizio Bossa, Walter Reinisch, K. A. Peterson, M. Ropeleski, S. Fishman, Marc Chevrier, Hans H Herfarth, Stephen B. Hanauer, Timothy H. Florin, Walter Fries, D. J. Hetzel, D. E. Elliott, János Banai, B. W. Behm, S. Sedghi, Remo Panaccione, Peter D.R. Higgins, Jean-Paul Achkar, Ziad Younes, Raja Atreya, Harald Vogelsang, M. Noar, S. S. Dhalla, U. Boecker, Raymond Bourdages, Ellen Scherl, Eran Goldin, T. Ritter, S. Gassner, Stefanie Howaldt, M. Ricci, Paolo Gionchetti, B. I. Leman, Marion Blank, D. Grunkmeier, Livia Biancone, J. Mudter, N. Chiba, Paolo Usai, R. Hardi, I. P. Beales, István Altorjay, W. J S Devilliers, J. Hill, Daniel C. Baumgart, Jason M. Swoger, Charles A. Sninsky, B. Singh Salh, L. D. Wruble, G. Bramkamp, Dario Sorrentino, Paul Rutgeerts, Stephen J. Bickston, S. Schreiber, D. J. Helper, Eric Lerebours, Jaroslaw Regula, M. D. Kreines, M. Strasser, C. Antoni, Giovanni Maconi, Freddy Cornillie, Laurent Peyrin-Biroulet, J. S. Hanson, Ewa Małecka-Panas, David Rowbotham, Jean-Charles Grimaud, Gerald Fraser, Ursula Seidler, C. Bünning, C. Berg, G. Reicht, Martin Lukas, John W. Popp, Edouard Louis, D. Laharie, Xavier Hébuterne, K. J. Brown, Márta Varga, L. Paradowski, Robert Ehehalt, Sandro Ardizzone, Stephanie Viennot, S. B. Hanauer, Charles N. Bernstein, Milan Lukas, H. Debinski, R. P. Schwarz, Simon Travis, D. I. Weinberg, D. Wallace, R. S. Stubbs, Bin Zou, A. Sloss, John Wyeth, Irit Avni-Biron, Peter Bossuyt, Ira Shafran, Matthieu Allez, Pierre Desreumaux, Michael Schultz, W. Reinisch, William J. Sandborn

Publikováno v: Gastroenterology, 150(7), 1568-1578. W.B. Saunders Ltd
Gastroenterology, Vol. 150, no. 7, p. 1568-1578 (2016)

Background & Aims Most patients with Crohn's disease (CD) eventually require an intestinal resection. However, CD frequently recurs after resection. We performed a randomized trial to compare the ability of infliximab vs placebo to prevent CD recurre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7679b1577e452cc22e168bc936ece45c
https://doi.org/10.1053/j.gastro.2016.02.072

Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial

Autor: Edward L. Krawitt, John W. Singleton, L. D. Wruble, Malcolm Robinson, Mark A. Peppercorn, Gary Gitnick, Stephen B. Hanauer

Publikováno v: Gastroenterology. 104:1293-1301

Background: Mesalamine is released from sulfasalazine in the colon and benefits colonic Crohn's disease. The mesalamine used in this study releases the drug throughout the small bowel and colon. Therefore, this study was designed to detect benefit fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::799399d88252ff50530525fd508d58e3
https://doi.org/10.1016/0016-5085(93)90337-c

Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group

Autor: A, Farley, L D, Wruble, T J, Humphries

Publikováno v: The American journal of gastroenterology. 95(8)

The objective of this study was to compare the efficacy and safety of the proton pump inhibitor rabeprazole to that of the histamine-2 (H2)-receptor antagonist ranitidine in the treatment of erosive gastroesophageal reflux disease. The primary indica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6d8f4470bccb0d54bb8be4562d54abf1
https://pubmed.ncbi.nlm.nih.gov/10950032

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

Autor: J W, Singleton, S B, Hanauer, G L, Gitnick, M A, Peppercorn, M G, Robinson, L D, Wruble, E L, Krawitt

Publikováno v: Gastroenterology. 104(5)

Mesalamine is released from sulfasalazine in the colon and benefits colonic Crohn's disease. The mesalamine used in this study releases the drug throughout the small bowel and colon. Therefore, this study was designed to detect benefit for Crohn's di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4fe419140c40918e5553e8402d7e0857
https://pubmed.ncbi.nlm.nih.gov/8039647

Toxic dilatation of the colon following barium enema examination during the quiescent stage of chronic ulcerative colitis

Autor: L. D. Wruble, Maury W. Bronstein

Publikováno v: The American Journal of Digestive Diseases. 13:918-924

A case is presented of toxic dilatation of the colon following barium enema examination after an 11-year remission of chronic ulcerative colitis. The role of this X-ray examination in chronic ulcerative colitis is discussed.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af99a1b2138c853a8cacdd8de4afa6c5
https://doi.org/10.1007/bf02237578